Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL EBITDA Margin

EBITDA as a percentage of revenue.

No reported EBITDA Margin figures are available to summarize.

EBITDA Margin history

Percent of revenue · from the income statement

No EBITDA Margin data reported for this period type.

EBITDA Margin vs competitors

How REPL compares with its peers on the latest reported figures

REPL Competitors Peer median
EBITDA Margin for REPL and competitors
Company Period LTM level YoY 3-year change
AGENAgenus Inc.LTM Mar 2026102.6% +184.0 pp+219.6 pp
CGENCompugen Ltd.LTM Mar 202648.0% +82.8 pp+491.0 pp
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
MGNXMacroGenics, Inc.LTM Mar 2026-32.2% -1.2 pp+32.0 pp
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-48.8% +93.1 pp—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-162.2% -191.7 pp+161.5 pp
JANXJanux Therapeutics, Inc.LTM Mar 2026-520.3% +290.5 pp-393.5 pp
IBRXImmunityBio, Inc.LTM Sep 2026-550.8% -269.0 pp+146419.7 pp
ADAGAdagene Inc.LTM Jun 2024-4420.7% —+613.1 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-770932.3% -482924.6 pp-730107.8 pp
REPLReplimune Group, Inc.FY2025— ——
Peer median (excluding REPL) -105.5%+82.8 pp+161.5 pp

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Revenue00000
Cost of Revenue4.14M4.58M000
Gross Profit(4.14M)(4.58M)000
Gross Margin—————
Research & Development57.49M80.65M126.53M174.96M189.45M
Selling, General & Admin21.13M36.26M000
Operating Expenses78.62M116.91M177.08M234.77M261.63M
Depreciation & Amortization4.14M4.58M2.45M5.08M5.93M
EBITDA(76.48M)(114.41M)(171.72M)(227.77M)(253.92M)
EBITDA Margin—————
Operating Income(82.76M)(121.48M)(177.08M)(234.77M)(261.63M)
Operating Margin—————
Interest Income916K390K10.01M23.36M21.12M
Interest Expense3.06M2.22M4.16M6.66M7.89M
Other Income / Expenses(915K)278K3.08M19.39M14.8M
Income Before Tax(83.68M)(121.21M)(174M)(215.39M)(246.83M)
Pre-Tax Margin—————
Income Tax Expense(2.81M)(3.17M)288K408K468K
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Net Margin—————
EPS (Basic)(1.75)(2.26)(2.99)(3.24)(3.07)
EPS (Diluted)(1.75)(2.26)(2.99)(3.24)(3.07)
Weighted Avg Shares46.25M52.21M58.21M66.57M80.56M
Weighted Avg Shares (Diluted)46.25M52.21M58.21M66.57M80.56M

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.